Report cover image

Generics BRIC (Brazil, Russia, India, China) Industry Guide 2019-2028

Publisher MarketLine
Published Dec 20, 2024
Length 223 Pages
SKU # MTLN19599835

Description

Generics BRIC (Brazil, Russia, India, China) Industry Guide 2019-2028Summary

The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights
  • Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $1,68,484.5 million in 2023. Russia was the fastest growing country with a CAGR of 16.2% over the 2019-23 period.
  • Within the generics industry, China is the leading country among the BRIC nations with market revenues of $1,21,016.7 million in 2023. This was followed by India, Russia and Brazil with a value of $22,824.0, $15,429.5, and $9,214.4 million, respectively.
  • China is expected to lead the generics industry in the BRIC nations with a value of $1,77,196.9 million in 2028, followed by India, Russia, Brazil with expected values of $31,455.5, $19,230.3 and $14,400.1 million, respectively.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC generics market
  • Leading company profiles reveal details of key generics market players’ BRIC operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the BRIC generics market with five year forecasts by both value and volume
  • Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country
Reasons to Buy
  • What was the size of the BRIC generics market by value in 2023?
  • What will be the size of the BRIC generics market in 2028?
  • What factors are affecting the strength of competition in the BRIC generics market?
  • How has the market performed over the last five years?
  • How large is the BRIC generics market in relation to its regional counterparts?

Table of Contents

223 Pages
1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 BRIC Generics
2.1. Industry Outlook
3 Generics in Brazil
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
4 Macroeconomic Indicators
4.1. Country data
5 Generics in China
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
6 Macroeconomic Indicators
6.1. Country data
7 Generics in India
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
8 Macroeconomic Indicators
8.1. Country data
9 Generics in Russia
9.1. Market Overview
9.2. Market Data
9.3. Market Segmentation
9.4. Market outlook
9.5. Five forces analysis
10 Macroeconomic Indicators
10.1. Country data
11 Company Profiles
11.1. Teva Pharmaceutical Industries Ltd
11.2. Viatris Inc
11.3. Sun Pharmaceutical Industries Ltd
11.4. Novartis AG
11.5. Sandoz Group AG
11.6. Hikma Pharmaceuticals Plc
11.7. Sanofi
11.8. Les Laboratoires Servier SAS
11.9. Stada Arzneimittel AG
11.10. Bayer AG
11.11. Lupin Ltd
11.12. Aspen Pharmacare Holdings Ltd
11.13. EMS SA
11.14. Eurofarma Laboratorios SA
11.15. Ache Laboratorios Farmaceuticos SA
11.16. Apotex Inc
11.17. Teva Canada Ltd
11.18. Sandoz Canada Inc
11.19. CSPC Pharmaceutical Group Ltd
11.20. Sino Biopharmaceutical Ltd
11.21. Hansoh Pharmaceutical Group Co Ltd
11.22. Dr. Reddy's Laboratories Ltd
11.23. Cipla Ltd
11.24. Aurobindo Pharma Ltd
11.25. PT Kalbe Farma Tbk
11.26. PT Indofarma Tbk
11.27. PT Sanbe Farma
11.28. PT Soho Global Health Tbk
11.29. Friulchem SpA
11.30. DOC Generici SRL
11.31. Recordati SpA
11.32. Daiichi Sankyo Co Ltd
11.33. Towa Pharmaceutical Co Ltd
11.34. Sawai Group Holdings Co Ltd
11.35. Toho Holdings Co Ltd
11.36. Laboratorios Silanes SA de CV
11.37. Pfizer Inc
11.38. Biocad
11.39. R-Pharm
11.40. Pharmstandard
11.41. AstraZeneca Plc
11.42. Bluefish Pharmaceuticals AB
11.43. Navamedic ASA
11.44. Novartis International AG
11.45. Beacons Pharmaceuticals Pte Ltd
11.46. Abbott Laboratories SA
11.47. Adcock Ingram Holdings Ltd
11.48. Dongkook Pharmaceutical Co Ltd
11.49. JW Holdings Corp
11.50. Hanmi Pharmaceuticals Co Ltd
11.51. Dong Wha Pharma Co Ltd
11.52. Esteve Pharmaceuticals SA
11.53. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
11.54. Deva Holding AS
11.55. Sandoz Inc
12 Appendix
12.1. Methodology
12.2. About MarketLine
List of Tables
Table 1: BRIC generics industry, revenue($m), 2019-28
Table 2: BRIC generics industry, revenue($m), 2019-23
Table 3: BRIC generics industry, revenue($m), 2023-28
Table 4: Brazil generics market value: $ million, 2018-23
Table 5: Brazil generics market volume: % of total pharma volume, 2018-23
Table 6: Brazil generics market geography segmentation: $ million, 2023
Table 7: Brazil generics market value forecast: $ million, 2023-28
Table 8: Brazil generics market volume forecast: % of total pharma volume, 2023-28
Table 9: Brazil Size of Population (million), 2019-23
Table 10: Brazil real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 11: Brazil GDP (Current Prices, $ Billion), 2019-23
Table 12: Brazil Inflation, 2019-23
Table 13: Brazil Consumer Price Index (Absolute), 2019-23
Table 14: Brazil exchange rate, 2018-23
Table 15: China generics market value: $ million, 2018-23
Table 16: China generics market volume: % of total pharma volume, 2018-23
Table 17: China generics market geography segmentation: $ million, 2023
Table 18: China generics market value forecast: $ million, 2023-28
Table 19: China generics market volume forecast: % of total pharma volume, 2023-28
Table 20: China Size of Population (million), 2019-23
Table 21: China real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 22: China GDP (Current Prices, $ Billion), 2019-23
Table 23: China Inflation, 2019-23
Table 24: China Consumer Price Index (Absolute), 2019-23
Table 25: China exchange rate, 2018-23
Table 26: India generics market value: $ million, 2018-23
Table 27: India generics market volume: % of total pharma volume, 2018-23
Table 28: India generics market geography segmentation: $ million, 2023
Table 29: India generics market value forecast: $ million, 2023-28
Table 30: India generics market volume forecast: % of total pharma volume, 2023-28
Table 31: India Size of Population (million), 2019-23
Table 32: India real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 33: India GDP (Current Prices, $ Billion), 2019-23
Table 34: India Inflation, 2019-23
Table 35: India Consumer Price Index (Absolute), 2019-23
Table 36: India exchange rate, 2018-23
Table 37: Russia generics market value: $ million, 2018-23
Table 38: Russia generics market volume: % of total pharma volume, 2018-23
Table 39: Russia generics market geography segmentation: $ million, 2023
Table 40: Russia generics market value forecast: $ million, 2023-28
Table 41: Russia generics market volume forecast: % of total pharma volume, 2023-28
Table 42: Russia Size of Population (million), 2019-23
Table 43: Russia real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 44: Russia GDP (Current Prices, $ Billion), 2019-23
Table 45: Russia Inflation, 2019-23
Table 46: Russia Consumer Price Index (Absolute), 2019-23
Table 47: Russia exchange rate, 2018-23
Table 48: Teva Pharmaceutical Industries Ltd: key facts
Table 49: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 50: Teva Pharmaceutical Industries Ltd: Key Employees
Table 51: Viatris Inc: key facts
Table 52: Viatris Inc: Annual Financial Ratios
Table 53: Viatris Inc: Key Employees
Table 54: Sun Pharmaceutical Industries Ltd: key facts
Table 55: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 56: Sun Pharmaceutical Industries Ltd: Key Employees
Table 57: Novartis AG: key facts
Table 58: Novartis AG: Annual Financial Ratios
Table 59: Novartis AG: Key Employees
Table 60: Sandoz Group AG: key facts
Table 61: Sandoz Group AG: Key Employees
Table 62: Hikma Pharmaceuticals Plc: key facts
Table 63: Hikma Pharmaceuticals Plc: Annual Financial Ratios
Table 64: Hikma Pharmaceuticals Plc: Key Employees
Table 65: Sanofi: key facts
Table 66: Sanofi: Annual Financial Ratios
Table 67: Sanofi: Key Employees
Table 68: Les Laboratoires Servier SAS: key facts
Table 69: Les Laboratoires Servier SAS: Key Employees
Table 70: Stada Arzneimittel AG: key facts
Table 71: Stada Arzneimittel AG: Key Employees
Table 72: Bayer AG: key facts
Table 73: Bayer AG: Annual Financial Ratios
Table 74: Bayer AG: Key Employees
Table 75: Bayer AG: Key Employees Continued
Table 76: Bayer AG: Key Employees Continued
Table 77: Lupin Ltd: key facts
Table 78: Lupin Ltd: Annual Financial Ratios
Table 79: Lupin Ltd: Key Employees
Table 80: Aspen Pharmacare Holdings Ltd: key facts
Table 81: Aspen Pharmacare Holdings Ltd: Annual Financial Ratios
Table 82: Aspen Pharmacare Holdings Ltd: Key Employees
Table 83: EMS SA: key facts
Table 84: EMS SA: Key Employees
Table 85: Eurofarma Laboratorios SA: key facts
Table 86: Eurofarma Laboratorios SA: Key Employees
Table 87: Ache Laboratorios Farmaceuticos SA: key facts
Table 88: Ache Laboratorios Farmaceuticos SA: Key Employees
Table 89: Apotex Inc: key facts
Table 90: Apotex Inc: Key Employees
Table 91: Teva Canada Ltd: key facts
Table 92: Teva Canada Ltd: Key Employees
Table 93: Sandoz Canada Inc: key facts
Table 94: Sandoz Canada Inc: Key Employees
Table 95: CSPC Pharmaceutical Group Ltd: key facts
Table 96: CSPC Pharmaceutical Group Ltd: Annual Financial Ratios
Table 97: CSPC Pharmaceutical Group Ltd: Key Employees
Table 98: Sino Biopharmaceutical Ltd: key facts
Table 99: Sino Biopharmaceutical Ltd: Annual Financial Ratios
Table 100: Sino Biopharmaceutical Ltd: Key Employees

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us